Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SNC-103 by Shanghai Simnova Biotechnology for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA...
SNC-103 by Shanghai Simnova Biotechnology for Systemic Lupus Erythematosus: Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Systemic Lupus Erythematosus. According to...
SNC-103 by Shanghai Simnova Biotechnology for Systemic Sclerosis (Scleroderma): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Systemic Sclerosis (Scleroderma). According to...
SNC-103 by Shanghai Simnova Biotechnology for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM). According...
SNC-115 by Shanghai Simnova Biotechnology for Small-Cell Lung Cancer: Likelihood of Approval
SNC-115 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Small-Cell Lung Cancer. According to...
SNC-115 by Shanghai Simnova Biotechnology for Neuroendocrine Carcinoma: Likelihood of Approval
SNC-115 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Neuroendocrine Carcinoma. According to GlobalData,...
SNC-102 by Shanghai Simnova Biotechnology for Relapsed Multiple Myeloma: Likelihood of Approval
SNC-102 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Relapsed Multiple Myeloma. According to...
SNC-102 by Shanghai Simnova Biotechnology for Refractory Multiple Myeloma: Likelihood of Approval
SNC-102 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Refractory Multiple Myeloma. According to...
SNC-103 by Shanghai Simnova Biotechnology for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
SNC-103 by Shanghai Simnova Biotechnology for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....
SNC-103 by Shanghai Simnova Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute...
SNC-103 by Shanghai Simnova Biotechnology for Non-Hodgkin Lymphoma: Likelihood of Approval
SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData,...